secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-083403
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 1.03, 2.04, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharmaceuticals files for Chapter 11; stalking horse sale of Zokinvy for up to $26M
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petitions on April 1, 2024 in Northern District of Texas.
- Stalking horse APA with Sentynl Therapeutics to buy Zokinvy for up to $26M, subject to court approval and higher bids.
- Patient access to Zokinvy (lonafarnib) to continue uninterrupted during the process.
- Company expects to sell substantially all assets and conduct an orderly wind down.
- Debt accelerated under Innovatus loan due to bankruptcy filing; enforcement stayed by Bankruptcy Code.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/0001193125-24-083403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524083403/d818699d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-083403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer